for me, the validity of a biased short seller in Street Sweeter releasing a negative analysis on Mitek can be compared to Cruz telling the voters in Iowa that Carson is no longer in the race and went home!!!
Since when do individuals or organizations that hold a short position have the opportunity to release a major negative "hit" piece where they stand to have significant profit as result?
to that end, it is interesting that the CEO, CFO and general manage all sold shares on May 2,2016. Is that a coincidence or an underlying reason (where there is smoke is there always fire?)
I still remember the pain when the stock price reached close to 7.5 several years ago and management announced secondary offering around 5.25 and stock price plummeted.
it seems that we shareholders are victims of a stock "that never misses an opportunity to miss an opportunity". For the last several months, everything seemed perfect with earnings, projections, new alliances and new customers. now this!!
it would be nice to have management respond to some of the key points in Street Sleeper's piece;
strength of IP, does USAA get to use mitek's technology free?, is USAA a threat in this sector?, can and will the banks and other financial institutions do their "own thing" or does it make more sense to outsource to company like Mitek?, are we ahead of most competitors?
not for management to answer, but are the payments to management higher and out of proportion to the size of the company and its revenues or are they justifiable rewards for a "job well done so far" and support the fact that often you have "to spend money to make money, and higher top people"
still long and hope that this was a unjustifiable hit piece from someone with vested interest to knock Mitek
Sentiment: Strong Buy
AEZS has lost countless millions ( any idea how much?) over the years trying to get approval for drugs in its pipeline. If purchased, do these losses transfer to the buyer with considerable tax savings? If so, besides acquiring a drug with retail value there should be considerable tax advantages reducing the actual cost to buyer. True?
0 for 2 for this very long, hoping company can go 1/3 and learned from previous mistakes in phase 3 trials
been investor in this company unfortunately longer than can remember; previous phase 3 studies on BPH and colon cancer failed miserably and unexpectedly and in retrospect the phase 2 studies did not have enough patients enrolled and also failed with growth hormone. So, AEZS has very poor track record (apparently not uncommon in late phase studies among biotechs). For those that are better at evaluating the structure of these studies, did they learn anything from their previous failures? Did they have enough enrolled in phase 2 to be reliable indicator for phase 3? Structured properly to meet scrutiny of FDA?
And we all know if the results are poor what we can expect of the stock price but what if the results are positive, encouraging ( mildly? very good?) what about the stock price? results released when?
Then what to expect from ovarian? prostate and other trials:
What if AEZS finally gets a phase 3 right after failing miserably the last several times and results are positive?
What could we expect the stock price to do?
Did he DSMB report breakdown the "events"? 250 patients enrolled on ZoptEC and 250 control.
Whether the results are MEANINGFUL to us as investors in AEZS really depends on if the 192 events that occurred were primarily in the control group rather than split with only a small margin favoring our drug.
In other words, "impressive results" or "merely acceptable results". "impressive" findings may result in
terminating the study early before 392 events or at least despite the mis-mangagment and heavy dilution eventually be reflected in significant stock price increase; however, we long investors know about "merely acceptable" findings which may even change for worse by the end of study, having experienced it 2 x already, unexpected I may add, which would doom the company.
So again, how many ZoptEC deaths were in the 192 compared to the control???? Did the poor response today to apparently "good news" reflect knowledge by some of that breakdown? If the company knows, they need to announce those results to all investors. I only hope that the percentage of events from both our drug and the control have not been revealed to anyone yet, but with this company's track record it is easy to become cynical.
all the prognostications and explanations from the pumpers and dumpers are meaningless without those numbers.
192 "events" have occurred since the start of the study, did the review board report to company
the breakdown of these events. Those results would be most meaningful esp if there was a wide gap between the control and our drug; that would be "impressive"; if the results 2 groups were close allowing for continuation of phase 3 but only "merely acceptable" not portend of great news in future. Are the results of the review board available or just the opinion to proceed.
in addition, the lack of response to report reflects again the mis-management by AEZS which resulted in massive dilution at no or minimal cost to large investors and manipulation of short sellers; being very long in time and with large loss, I fear that this stock with hundreds of millions of shares ( not sure how many) will continue to be manipulated and has limited upside; will hold because selling at these levels does not help and even a faint glimmer of hope of recovery is better than none.
Does firing Turpin on the eve of reporting Phase 3 results portend "bad news"? The former VP and long time
CFO has been with company greater than 10 years. Is he the scapegoat for bad management decisions?
Why now? Has news leaked to the company that the results were inconclusive or negative. If so, the company will not survive whatever it does! Sort of arranging the deck chairs aboard the Titanic. If no news leak, then again why now and why is this going to gain support in financial community? Closing office in Canada belt tightening?
With all the benefits of the 3D solar cell, we hear nothing about status regarding its acceptance in the industry, adoption by anyone, how long to find partner , commercialization , etc
Are they still refining and developing? If not, why is it not being produced or coming closer to the market?
been a Mitek shareholder for quite some time and frustrated because while several consecutive quarters of positive earnings encourages management during conference calls, the street yawns and the stock labors within narrow range. The positive earnings are incremental, only several hundred thousand dollars each time and at that rate it seems it will take years to reach a number the street considers significant enough to move the stock even to the area over 7 ( before that ridiculous offering 2 dollars below at 5.25). What will it take or will it ever have exponential ( millions instead of mere hundreds of thousands) to move the stock and silence the shorts?????? In other words, despite the large number of apparent "users" of the technology, is the pricing model flawed and will it and will it continue this way or can it change????
down 8 points past 2 days despite market up 450. I know there was no reason for the rapid climb over 50 end of dec; however, is there a reason for this decline? any leakage on phase 3 results? when is or has phase 3 been completed? when can we expect report on results?
as long time investor in this company , I am amazed, befuddled, whatever you want to call my disappointment
in a stock with a reasonably good earnings and upbeat CC that drops in price to current level and doesn't have an uptick despite market up 450 points last 2 days. Any rational explanation?
Now do we have to wait 3 months to next earnings report for next transient uptick? what will cause it to go up before that?
Having been an investor for over 10 years, the only positive event was splitting off the vitamin company which resulted in less of a total loss in investment. Unfortunately, your analysis and comments are right on!!!!!
With more dilutions and reverse splits, even a successful phase 3 will only result in a modest recovery of losses and that assumes that management can be successful at anything.
undervalued???? promises, promises.........I have lost a fortune on this stock because of 3 failures to pass phase 3 or the last gain an FDA approval. The first 2 involved drugs with great phase 2 although small size and company "blindsided" by poor phase 3 ( KERX survived and flourished reaching new highs post ffailure).
The last it seems was destined to fail with comments from the FDA and I do not understand why company even went forward following those. Because of the above failures , stock dropped and dropped and then reversed split and dropped and drop some more.
Does anyone really believe that this company can complete a FDA approved phase 3 with success and then get approval??? If their track record is any evidence against this happening, this stock is overvalued at present. At ..57, I will continue to hold and hope management will finally reward shareholders. In meantime, all stock options should be suspended or at least tied to the stock price; otherwise, the only beneficiaries of all these failures continue to the management team.
do not understand why shorts are so interested in this $3 stock? isn't there more to be gained by shorting a higher price stock and driving it downward? Other than reporting higher revenues and earnings is there anything the company can do to blunt the effect of the shorts and naysayers? It seems that the good news at the end of last quarter had a short term positive effect and then the stock headed south. In the face of a healthy stock market and news better than expected, why has this stock failed to maintain an upward trend?
Would it help if management offered to connect their stock options and bonuses with performance of the stock ( and therefore have more skin in the game like us investors) and also managed their selling and disposal of these gifted shares in a more appropriate time frame so as not to dampen even small upward blips in stock?
Sentiment: Strong Buy
Just curious what kind of leading provider of financial services is trading at less than $1.50
and has so little cash in the account?? Aren't there more substancial providers interested in partnering with Mitek? This partnership agreement certainly does not excite the Street so far or myself. Am I wrong to feel this way about it?
Sentiment: Strong Buy
As Mitek drifts downward slightly and volume low after positive earnings, do we have to wait 3 months for hopefully another good report to propel the stock upward or what other factors might cause it to move upwards
Sentiment: Strong Buy
Better than expected good news and the response of stock disappointing! Explanation?
What is it going to take to have this stock make a sig move upwards? How does stock counter the grip the shorts seem to have? Bad news pummels the stock and yet good news barely moves it.
During CC, current management shifted responsibility of purchasing rights to Marilen on previous management team who apparently reviewed and liked phase 2 studies done by another company.
Current management unclear and shifted to one another but it appears that they accepted phase 2 studies done elsewhere and did not do due exhaustive review of their own before starting phase 3. This does not seem like an appropriate course of action.
To make things worse, after phase 3 data in ( over 2 years ago) why didn't the FDA review the results
and point out the tragic flaws of the phase 2 and 3 studies before encouraging or permitting AEZS to go forward with the time consuming, costly, diluting process to obtain NDA? The last 2 years were a total waste of resources and time and never should have occurred if the FDA would have acted responsibility and alerted the company to the flaws. Approval never had a chance.
So who to blame for this fiasco???? Current management for pushing forward without really determining the validity of previous studies and accepting previous management's assessment.!! The FDA for not providing the guidance necessary to halt process of seeking approval.
The losers, we shareholders again!!!!!!!!
How much of us have confidence that AEZS can plan and carryout a successful phase 3 on endometrial cancer drug????
Since it seems that the sales force hired for Macrilen was linked to Ascend's sales reps, what does the future hold?? Why would Ascend tie its future to a company like AEZS at this time? Wouldn't count on it!!!